Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.48 |
| ▸ | PYGL | P06737 | 7/20 | 0.47 |
| ▸ | PYGM | P11217 | 5/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15540370 | 1.00 | RIPK1 (0.48) | RIPK1PYGLPYGMBRD4NQO2 | |
| SCHEMBL2840163 | 0.88 | NQO2 (0.46) | RIPK1PYGLPYGMBRD4NQO2 | |
| SCHEMBL4214219 | 0.86 | RIPK1 (0.61) | RIPK1PYGLPYGM | |
| SCHEMBL3924254 | 0.86 | RIPK1 (0.61) | RIPK1PYGLPYGM | |
| SCHEMBL15540773 | 0.85 | RIPK1 (0.38) | RIPK1PYGLPYGMBRD4NQO2 | |
| SCHEMBL30767932 | 0.82 | GAA (0.45) | RIPK1PYGLPYGMBRD4NQO2 | |
| SCHEMBL653580 | 0.82 | GAA (0.45) | RIPK1PYGLPYGMBRD4NQO2 | |
| SCHEMBL5133011 | 0.82 | GAA (0.45) | RIPK1PYGLPYGMBRD4NQO2 | |
| SCHEMBL653581 | 0.82 | GAA (0.45) | RIPK1PYGLPYGMBRD4NQO2 | |
| SCHEMBL15541576 | 0.80 | PYGL (0.64) | RIPK1PYGLPYGMBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| EP-4222143-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | Katholieke Universiteit Leuven (BE) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | RIPK1 1424/4885PYGL 449/4885PYGM 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.